Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of oral hexavalent recombinant rotavirus attenuated live vaccine (Vero cells) in healthy infants
ChiCTR2500106727Phase 2Completed
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Wusheng Erlunbao in rotaviral diarrhea (3 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Serum IgA seroconversion rate against vaccine-type rotavirus 28 days after full immunization and Incidence of adverse events and reactions from first dose to 42 days after last dose. Started Jul 2025; status: completed.
02
Drugs
Wusheng Erlunbao
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on ChiCTR2500106727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106727.